Fulgent Bundle
How did Fulgent transform diagnostics during COVID-19?
Fulgent rapidly scaled from niche genomic services to high-throughput COVID-19 testing, growing revenue from about $32 million in 2019 to over $992 million in 2021 by pairing NGS, proprietary bioinformatics, and automation.
Founded in 2011 in Temple City, California, Fulgent built a software-defined lab integrating sequencing, informatics, and automation to serve rare disease, oncology, and reproductive health; post-2021 it refocused on hereditary and oncology diagnostics.
What is Brief History of Fulgent Company? Fulgent went public in 2016, expanded via the 2022 Inform Diagnostics acquisition, and now emphasizes precision oncology and pathology scale; see Fulgent Porter's Five Forces Analysis.
What is the Fulgent Founding Story?
Fulgent was founded on May 13, 2011, by Ming Hsieh, Hanlin Gao, and Paul Kim to simplify clinical NGS by integrating wet-lab, informatics, and reporting into a single platform.
Founding Story
Seeded mainly by founder capital and early customer cash flow, Fulgent Genetics launched with a menu-based clinical testing model, fast turnaround, and lower list prices than legacy peers.
- Ming Hsieh provided capital discipline and platform vision after selling Cogent Systems to 3M for roughly $943,000,000 in 2010.
- Hanlin Gao led development of the proprietary bioinformatics pipeline that reduced per-sample variable cost.
- Paul Kim added operational and financial expertise to scale a CLIA-certified, CAP-accredited laboratory model.
- Early focus: hereditary disease panels with typical turnaround of 2–3 weeks and payer-billed per-test pricing while building an in-house LIMS and analytics stack.
Key early challenges included validation and payer coverage; the founders navigated these while bootstrapping product development and positioning Fulgent for later growth and public markets; see more in the article Marketing Strategy of Fulgent.
Fulgent SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
What Drove the Early Growth of Fulgent?
Early Growth and Expansion traces Fulgent’s shift from single-gene diagnostics to a broad genomics and pathology platform, accelerated by an IPO and a pandemic-era pivot that generated substantial revenue and enabled strategic acquisitions.
2014–2016: Platform build and clinical credentials
Between 2014 and 2016 Fulgent expanded from single-gene tests to multi-gene panels across rare disease and oncology, obtained CLIA/CAP accreditation, and established relationships with pediatric geneticists and academic centers. The company completed its IPO in September 2016, raising approximately $50 million gross to scale test development and commercial reach.
2017–2019: Menu expansion and payer traction
By 2019 the test menu exceeded 18,000 genes across thousands of condition-focused panels, introduced exome options, and enabled international ordering. First major payer contracts and hospital system agreements increased volumes; 2019 revenue reached about $32 million, with hereditary testing as the core.
2020–2021: COVID pivot and scale
COVID-19 catalyzed rapid deployment of high-throughput RT-PCR and NGS-based surveillance, with automation and informatics enabling processing of tens of thousands of tests per day. Revenue rose to approximately $421 million in 2020 and ~$992 million in 2021, generating significant cash used to expand oncology and pathology capabilities.
2022–2023: M&A and strategic refocus
The acquisition of Inform Diagnostics for roughly $170 million added a national anatomic pathology network and GI/dermatopathology expertise, enhancing oncology workflows and cross-selling. As COVID testing normalized, revenue declined industry-wide; Fulgent pivoted toward germline oncology, somatic profiling, reproductive health, and pharma services while optimizing costs.
2024–H1 2025: Post‑COVID core and differentiation
Management emphasized a 'post-COVID core' focused on somatic NGS panels, MRD initiatives, hereditary cancer, carrier screening, and pharma partnerships. Cash and short-term investments accrued during the pandemic funded R&D and tuck‑ins, while the company targeted operating leverage, payer expansion, and cross-selling via Inform Diagnostics' integrated pathology.
Competitive and strategic positioning
Competitive dynamics include large reference labs (Quest, Labcorp), specialized genomics peers (Invitae, Natera, Guardant, Exact Sciences), and regional hospital labs. Fulgent’s differentiation rests on platform cost, rapid menu build-out, and integrated pathology from Inform Diagnostics, supporting growth in oncology testing and pharma services. Read more in this article on the Growth Strategy of Fulgent.
Fulgent PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
What are the key Milestones in Fulgent history?
Milestones, Innovations and Challenges of the company include rapid scale-up of a proprietary end-to-end genomics platform, expansion across rare disease, oncology, reproductive and infectious testing, CLIA/CAP certification, Inform Diagnostics integration for combined molecular-plus-morphology workflows, pandemic-era national contracts, and post-2021 strategic reallocation to oncology and biopharma services.
| Year | Milestone |
|---|---|
| 2011 | Founding and early clinical sequencing operations established to offer NGS-based diagnostics |
| 2019 | Secured CLIA/CAP certifications and expanded payer coverage for clinical genomic tests |
| 2020 | Scaled to national COVID-19 testing contracts, dramatically increasing revenue and capacity |
| 2021 | Peak pandemic testing followed by rapid normalization; began reallocating cash to M&A and oncology build-out |
| 2022 | Acquired Inform Diagnostics to scale anatomic pathology and enable integrated molecular-plus-morphology workflows |
| 2023 | Launched expanded hereditary cancer panels, exome-based diagnostics and solid-tumor profiling for CGP |
The company built a proprietary stack: custom LIMS, automated wet-lab workflows, bioinformatics pipelines and variant curation tools that enabled rapid menu shifts. It also supported pharma with NGS services and trial testing, and pursued liquid biopsy research and somatic tumor profiling collaborations.
Proprietary LIMS & Informatics
Custom laboratory information management and bioinformatics enabled rapid assay deployment and automated reporting across clinical and research workflows.
Comprehensive Test Menu
Expanded offerings include hereditary cancer panels, exome-based diagnostics, somatic CGP panels and reproductive/infectious assays to serve diverse clinical needs.
Pathology Integration
Acquisition of anatomic pathology capabilities enabled combined morphology-plus-molecular reporting important for solid-tumor workflows.
Oncology & Pharma Services
NGS services for biopharma and clinical trial testing provided recurring revenue and strengthened partnerships with sponsors and CROs.
Liquid Biopsy Research
Collaborations in circulating tumor DNA and MRD research positioned the company within emerging precision oncology use cases.
Rapid Pandemic Deployment
Platform agility supported scaling to national COVID testing contracts and high-throughput operations during 2020–2021.
Challenges included sharp reimbursement pressure in hereditary testing, intense competition in oncology NGS and MRD, and a post-2021 collapse in COVID testing that reduced revenue from pandemic highs and forced expense realignment. The company normalized demand by reallocating pandemic cash to M&A, assay development and commercial expansion while pruning excess COVID-era capacity.
Reimbursement Pressure
Hereditary testing faced downward reimbursement trends, requiring pricing and payer strategy adjustments to preserve margins.
Market Competition
Oncology NGS and MRD segments saw intensified competition from established and emerging players, pressuring share and pricing.
Post-Pandemic Revenue Drop
COVID testing collapse after 2021 materially reduced top-line revenue, necessitating cost cuts and strategic pivots toward oncology and pharma services.
Capacity Optimization
Pruning excess lab capacity and repurposing equipment and personnel were required to align fixed costs with normalized demand.
Payer Contracting
Expanding payer coverage required evidence generation and negotiated coverage policies to support clinical test uptake.
Strategic Reinvestment
Pandemic-era cash was redeployed into acquisitions, R&D and commercial hires to drive longer-term oncology and pharma revenue streams.
Platform agility, owning both informatics and wet-lab operations, and diversified revenue across oncology, hereditary, pathology and pharma proved critical to adapt to cyclicality and capitalize on guideline-driven germline testing and increasing CGP utilization; see further context in Competitors Landscape of Fulgent.
Fulgent Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What is the Timeline of Key Events for Fulgent?
Timeline and Future Outlook of Fulgent company: concise chronology from the 2011 founding to 2025 strategic focus, highlighting regulatory milestones, pandemic-driven growth, the Inform Diagnostics acquisition, and the shift toward oncology-led diagnostics and biopharma services.
| Year | Key Event |
|---|---|
| 2011 | Company founded May 13 in Temple City, CA by Ming Hsieh, Hanlin Gao, and Paul Kim to deliver affordable, accurate clinical genomics. |
| 2014 | CLIA/CAP approvals secured, enabling national clinical testing and expansion into multi-gene hereditary panels. |
| 2016 | IPO on Nasdaq (FLGT), raising approximately $50M to scale R&D and commercial operations. |
| 2017 | Launch of exome-based offerings with growth in pediatric rare disease and oncology panels. |
| 2019 | Revenue reached about $32M, with broader payer contracts and hospital system relationships. |
| 2020 | Rapid pivot to COVID-19 testing; revenue surged to roughly $421M driven by large public-sector contracts. |
| 2021 | Peak pandemic revenue near $992M, significant cash generation and capacity build-out. |
| 2022 | Acquisition of Inform Diagnostics for about $170M, adding anatomic pathology and oncology capabilities. |
| 2023 | Post-COVID normalization; refocus on germline oncology, somatic NGS, reproductive health, pharma services, and cost optimization. |
| 2024 | Investments in oncology CGP, liquid biopsy research, MRD initiatives, and integration of molecular and pathology workflows. |
| 2025 | Continued shift toward oncology-led growth, payer expansion, biopharma partnerships, selective tuck-in M&A, and automation using cash reserves. |
Near-term growth outlook
Management targets mid- to high-single-digit core diagnostics growth, with upside from oncology CGP adoption and pathology-integrated reporting.
Oncology and MRD focus
Priorities include scaling tumor profiling (solid and liquid) and enhancing MRD assays to capture higher-value oncology workflows.
Payer and hospital integration
Expanding hereditary cancer coverage and deepening hospital-system integrations aim to drive durable, recurring revenue and improved utilization.
Capital allocation & M&A
Disciplined capital allocation with selective tuck-in acquisitions and automation investments to improve operating leverage and turnaround time.
Industry tailwinds—expanding oncology guidelines, value-based care, and companion diagnostics—support demand for Fulgent Genetics services; see additional context in the Target Market of Fulgent article.
Fulgent Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Competitive Landscape of Fulgent Company?
- What is Growth Strategy and Future Prospects of Fulgent Company?
- How Does Fulgent Company Work?
- What is Sales and Marketing Strategy of Fulgent Company?
- What are Mission Vision & Core Values of Fulgent Company?
- Who Owns Fulgent Company?
- What is Customer Demographics and Target Market of Fulgent Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.